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Objective. Recent reports have confirmed associ-
ation of single-nucleotide polymorphisms (SNPs) map-
ping to the interleukin-23 receptor (IL-23R) and IL-12
genes with psoriasis susceptibility. The aim of this study
was to determine whether these variants are also asso-
ciated with susceptibility to psoriatic arthritis (PsA).
Methods. Two IL23R SNPs (rs7530511 and
rs11209026) and 2 IL12B SNPs (rs3212227 and
rs6887695) were genotyped in DNA samples from 520
white patients with PsA and 2,260 control subjects, all
of whom resided in the UK. For SNP rs3212227, data
on a larger group of controls (n  4,681) were publicly
available; this information was used in the analysis.
Genotype counts were compared between patients with
PsA and population controls, using the trend test.
Results. A haplotype comprising carriage of the
common variants of both IL23R SNPs was associated
with PsA susceptibility (adjusted P  0.013 [1,000
permutations]). Both IL12B SNPs were independently
associated with PsA susceptibility, and this association
was strongest under a dominant model, with homozy-
gosity for the common allele being more frequent in
patients with PsA than in control subjects: for rs3212227,
the odds ratio (OR) for carriage of AA versus other
genotypes was 1.43 (95% confidence interval [95% CI]
1.17–1.76); for rs6887695, the OR for carriage of GG
versus other genotypes was 1.43 (95% CI 1.18–1.74).
Conclusion. Variation within IL23R and IL12B is
associated with susceptibility to both psoriasis and PsA.
The effect sizes observed in patients with PsA appear to
be smaller than those previously reported in patients
with psoriasis, suggesting that both loci are primarily
associated with psoriasis susceptibility. However, this
does support the idea that the genetic etiology of the
psoriasis present in patients with PsA has susceptibility
loci in common with those observed in patients with
uncomplicated psoriasis.
Psoriatic arthritis (PsA) may be defined as “an
inflammatory arthritis associated with psoriasis which is
usually negative for rheumatoid factor [RF]” (1). Like
other complex diseases, PsA is considered to be trig-
gered by an unknown environmental agent in a geneti-
cally susceptible individual. A strong genetic component
to disease etiology has been demonstrated, with studies
from the UK estimating the sibling recurrence risk (s)
to be 47 and the heritability to be 100% (2). However,
few susceptibility genes have been identified, and none
have been confirmed as predisposing to PsA indepen-
dently of psoriasis. For example, several studies have
identified association of PsA with the known psoriasis
susceptibility allele HLA–Cw0602, but the association
appears to be primarily with type 1 psoriasis (age at
onset of psoriasis 40 years) rather than type 2 psoriasis
(age at onset of psoriasis 40 years) or PsA itself (3).
Recently, association of single-nucleotide poly-
morphisms (SNPs) within the interleukin-23 receptor
gene (IL23R) and a gene encoding a subunit of its
ligand, IL12B, have been reported to be associated with
psoriasis (4). The 2 genes contributed to psoriasis sus-
ceptibility independently of each other, and subsequent
studies have confirmed association with both genes,
which have an additive but not an interactive effect with
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3705each other (5,6). Psoriasis and PsA occur together and
share the skin phenotype, similarity in cytokine profiles,
and the response to anti–tumor necrosis factor biologic
therapies, suggesting that they are likely to share some
etiologic pathways. Hence, we hypothesized that com-
mon genetic factors may underlie these conditions. The
aim of the current study was to investigate the role of the
IL23R and IL12B polymorphisms in determining suscep-
tibility to PsA.
PATIENTS AND METHODS
This study was approved by the North West Multicen-
tre Research Ethics Committee (MREC 99/8/84), and all
subjects provided informed consent.
Samples. DNA samples were available from patients
with PsA (n  520) and population controls. All subjects were
white and resided in the UK. PsA was defined as the presence
of both psoriasis and inflammatory arthritis, regardless of RF
status; details of recruitment to the study have been described
previously (3). All cases satisfied the recently published CAS-
PAR (ClASsification criteria for Psoriatic ARthritis) classifi-
cation criteria for PsA (7). Genotyping was performed on
DNA samples obtained from control subjects recruited from
among blood donors or from the British 1958 Birth Cohort
DNA collection, which is a random subset of individuals born
in the UK in one week in March 1958 (n  2,260). For one
SNP (rs3212227), data on a larger group of controls (n 
4,681) were publicly available (www.b58cgene.sgul.ac.uk/), and
these data were used in the analysis.
Genotyping. Four SNPs were selected for genotyping.
These included the 2 SNPs mapping to the IL23R gene,
rs11209026 and rs7530511, and the 2 SNPs mapping to the
IL12B gene, rs6887695 and rs3212227, all of which have pre-
viously been associated with psoriasis susceptibility (4–6).
Genotyping was performed using the Sequenom MassARRAY
platform (Sequenom, San Diego, CA). It should be noted that
for 2 SNPs (rs11209026 and rs6887695), the samples from PsA
patients have been genotyped previously and the frequencies
have been published as part of a separate study (8). Genotype
data on patients with type 1 psoriasis presenting to a derma-
tology clinic in whom a diagnosis of PsA had been excluded
(n  233) were also available, and these data have been pub-
lished previously as part of a larger cohort of samples from
patients with psoriasis (5).
Statistical analysis. Genotype and allele carriage fre-
quencies were compared between patients with PsA and
population controls, using the chi-square test implemented using
Stata software (StataCorp, College Station, TX). Haplotype
analysis was performed using Haploview software (Broad
Institute, Cambridge, MA) with 1,000 permutations, to pro-
duce an adjusted P value (9).
RESULTS
Genotype frequencies for both patients with PsA
and control subjects conformed to Hardy-Weinberg
expectations, and allele frequencies were similar to
those reported previously (8).
Both the rs7530511 and the rs11209026 SNPs
mapping to IL23R showed borderline evidence for asso-
ciation with PsA, using the trend test (Table 1). The
rs11209026 SNP encodes an arginine-to-glutamine sub-
stitution, and previous reports have suggested that the
rare glutamine variant is overrepresented in control
subjects compared with patients with psoriasis (10). This
was not shown to be the situation for patients with PsA,
for whom minor allele frequencies were similar to those
in the control population (minor allele frequencies of
0.05 and 0.07, respectively). The IL23R SNP rs7530511
also encodes a nonsynonymous substitution of lysine to
proline. Although the correlation between the 2 SNPs
was low (r
2  0.07), there was evidence for linkage
disequilibrium (D1); therefore, haplotype analysis was
undertaken. Carriage of the common haplotype has
been previously associated with susceptibility to pso-
riasis (4). Carriage of the haplotype of common variants
was more frequent in patients with PsA than in control
subjects (P  0.005). The adjusted P value (after 1,000
permutations) remained statistically significant (P 
0.013) (Table 2).
Both of the SNPs mapping to IL12B, rs3212227
and rs6887695, showed statistically significant evidence
for association (Table 1). For both SNPs, the association
was strongest under a dominant model, with 2 copies of
the common allele being associated with PsA suscepti-
bility, as has been reported previously with susceptibility
to psoriasis (4).
The correlation between the 2 SNPs mapping to
IL12B was low (r
2  0.21), suggesting that the 2 variants
do not lie on a single associated haplotype. Because only
summary data, and not individual-level data, were avail-
able for control subjects for one of the IL12B SNPs
(rs3212227), it was not possible to undertake haplotype
analysis.
It should be noted that the effect sizes for the 2
SNPs mapping to IL23R are lower for PsA than those
that have been reported for psoriasis. This may suggest
that the primary association is with type 1 psoriasis,
because previous reports have been largely restricted to
this subgroup. Indeed, in our own series and others, the
frequency of HLA–Cw0602 is lower in PsA samples
than in psoriasis samples, particularly in the type 1
subgroup (3,11). In order to explore this further, pa-
tients with PsA were stratified by their age at the onset
of psoriasis: patients with type 1 PsA were defined as
those who were age 40 years or younger at the onset of
psoriasis, and patients with type 2 PsA were defined as
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psoriasis. Stratification by age at the onset of psoriasis
showed that association of the rs7530511 SNP was stronger
in patients with type 1 psoriasis. Interestingly, both
IL12B SNPs showed a trend toward stronger evidence
for association in the subgroup of patients with type 2
PsA compared with the control group, although this was
based on smaller numbers of patients in the subgroup of
patients with type 2 PsA (Table 1).
To further explore whether the primary associa-
tion is with psoriasis rather than with PsA, carriage of 2
copies of the common allele of each SNP was compared
between patients with type 1 psoriasis in whom PsA had
been excluded and control subjects. For the IL23R SNPs,
effect sizes were higher in patients with type 1 psoriasis
than in patients with PsA (for rs11209026, OR 2.0; for
rs7530511, OR 4.8). For the IL12B SNPs, the effect sizes
in patients with type 1 PsA were similar to those in
patients with type 1 psoriasis (for rs3212227, OR 1.4; for
rs6887695, OR 1.3), supporting the hypothesis that the
association is primarily with psoriasis.
Subgroup analysis in RF-negative patients with
PsA was performed, and the effect sizes in this sub-
group were similar to those in the cohort as a whole
(OR 1.41, 1.27, 1.45, and 1.49 for rs7530511, rs11209026,
rs6887695, and rs3212227, respectively).
DISCUSSION
In this large case–control study, we observed that
polymorphisms in the IL12B and IL23R genes, both of
which were previously associated with psoriasis, are also
associated with susceptibility to PsA. The associations of
the IL12B locus with PsA are stronger than those with
the IL23R gene (which showed statistically significant
evidence for association only when analyzed by haplo-
type), with carriage of both common variants predispos-
ing to PsA.
The huge overlap in the clinical phenotype of
Table 1. Genotype comparisons between patients with PsA and controls for SNPs mapping to IL23R and IL12B*
Locus/
gene/
genotype Patients Controls
P, patients
versus controls
OR (95% CI)†
PsA overall Type 1 PsA Type 2 PsA
rs7530511
IL23R
TT 415 (81.3) 1,663 (77.4) 0.06‡ 1.27 (0.99–1.64) 1.35 (1.01–1.81) 1.09 (0.70–1.75)
TC 88 (17.3) 448 (20.9)
CC 7 (1.4) 36 (1.7)
rs11209026
IL23R
GG 469 (90.3) 1,922 (87.0) 0.04‡ 1.40 (1.01–1.96) 1.33 (0.93–1.95) 1.59 (0.84–3.31)
GA 48 (9.3) 277 (12.5)
AA 2 (0.4) 10 (0.5)
rs3212227
IL12B
AA 382 (72.5) 3,032 (64.7)§ 0.001¶ 1.43 (1.17–1.76) 1.32 (1.05–1.68) 1.72 (1.13–2.68)
AC 136 (25.8) 1,478 (31.6)
CC 9 (1.7) 171 (3.7)
rs6887695
IL12B
GG 283 (54.5) 1,021 (45.7) 4.2  10
5‡ 1.43 (1.18–1.74) 1.29 (1.04–1.62) 1.80 (1.23–2.64)
GC 207 (39.9) 1,006 (44.9)
CC 29 (5.6) 212 (9.4)
* Values are the number (%). PsA  psoriatic arthritis; SNPs  single-nucleotide polymorphisms; OR  odds ratio; 95% CI 
95% confidence interval.
† Versus other genotypes.
‡ For trend.
§ Information on control genotype frequencies obtained from published data (www.b58cgene.sgul.ac.uk/).
¶ Genotypic, calculated using the chi-square test because only summary genotype count data were available.
Table 2. Frequency of IL23R single-nucleotide polymorphisms in
patients with psoriatic arthritis and control subjects*
Haplotype Patients Controls PP , adjusted†
TG 85.0 81.2 0.005 0.013
CG 10.1 12.1
TA 0.05 0.07
* Values are the percent.
† With 1,000 permutations.
SHARED SUSCEPTIBILITY BETWEEN PSORIASIS AND PsA 3707PsA with inflammatory arthritis and psoriasis means that
separating the genetic contributions to PsA from the
contributions of the constituent components of PsA is a
difficult challenge. Because effect sizes reported previ-
ously in studies of psoriasis are larger than those ob-
served for PsA in the current study, it is suggested that
the association is primarily with psoriasis. Indeed, a
recent study of UK patients with psoriasis demonstrated
ORs of 1.67, 1.98, 1.38, and 1.72 for the rs11209026 and
rs7530511 IL23R SNPs and the rs3212227 and rs6887695
IL12B SNPs, respectively (5). A subsample of the pa-
tients with psoriasis investigated in that study had been
specifically examined for the presence of PsA; for those
with type 1 psoriasis alone, ORs were higher than or
equivalent to the ORs for patients with type 1 PsA, sup-
porting the idea that the primary association is with
psoriasis.
Although not all of these polymorphisms have
been tested directly for association with inflammatory
arthritis, results from imputed data from a large genome-
wide association study in 1,860 patients with rheumatoid
arthritis (RA) and 2,930 population controls did not
show any evidence for association with RA for either the
IL23R SNPs (for rs11209026, P  0.18 [directly geno-
typed by the Wellcome Trust Case Control Consortium];
rs7530511, P  0.20 [from imputed data]) or the IL12B
SNPs (for rs6887695, P  0.40; for rs3212227, P  0.79
[both from imputed data]). Confidence scores for im-
puted genotypes exceeded 99%, and, at such levels,
imputation has previously been shown to be 98.4%
accurate (12). Hence, the IL23R and IL12B loci appear
to be associated with psoriasis and PsA but not with
inflammatory arthritis in the form of RA.
The possibility that inclusion of RF-positive pa-
tients in the current series may have diluted the observed
effect of the IL12B and IL23R variants in PsA suscepti-
bility should be considered, particularly because some of
these patients may be found to have RA with coinciden-
tal psoriasis. In order to address this possibility, the
analysis was repeated, restricted to the RF-negative sub-
group. However, effect sizes similar to those seen in the
PsA group as a whole were detected, when compared
with controls, suggesting that RF is not a significant
covariant.
For both psoriasis and PsA, a haplotypic effect at
IL23R, with carriage of the common variants of both
polymorphisms being associated with disease suscepti-
bility, has been observed, suggesting that either both are
acting as markers with an as yet ungenotyped variant
with which they are both in linkage disequilibrium or
that multiple susceptibility effects are present at the
same locus. Both IL23R SNPs encode nonsynonymous
amino acid substitutions. SNP rs11209026 encodes an
arginine-to-glutamine substitution at codon 381 (R381Q)
within the JAK-2–binding domain, but the results of
function studies of this variant have not yet been re-
ported (10).
A haplotypic effect is also seen at the IL12B locus,
where independent effects of IL12B polymorphisms are
also present. One of the associated SNPs, rs321227, lies
in the 3-untranslated region of the genes and has pre-
viously been reported to affect both IL-12 and IL-12 p40
expression, but findings have been inconsistent. This may
be explained by the presence of a second effect within
the gene, which was not accounted for in those function
studies. Resequencing, fine mapping, and further func-
tion studies will be required to explore how these poly-
morphisms predispose to disease. Interestingly, an anti–
IL-12 antibody–based treatment is currently undergoing
clinical trials for the treatment of psoriasis, and it will be
intriguing to note whether any benefit is also observed in
patients with PsA, not only in terms of the skin but also
in terms of joint involvement. Indeed, preliminary data
(which, to date, have been presented in abstract form only)
suggest that a fully human anti–interleukin-12/23 monoclo-
nal antibody might have efficacy in treating inflammatory
arthritis in active PsA (13).
In summary, we report association of a haplotype
mapping to IL23R and 2 SNPs mapping to IL12B with
susceptibility to PsA. The finding of shared susceptibility
between psoriasis and PsA supports the findings of other
studies, including studies of the HLA–Cw06 locus,
which suggest that the genetic factors underlying skin
involvement in PsA are no different from those under-
lying psoriasis without coexistent arthritis. Genome-wide
association studies of PsA, therefore, have the potential
to identify novel psoriasis susceptibility genes as well as
additional PsA susceptibility genes. Results of genome-
wide association studies in psoriasis and PsA currently
under way will allow comparison with the data from
recent RA genome-wide studies and permit a thorough
exploration of the overlap between the conditions (14).
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